Latest News
Job Opportunity – Programme Officer
Concept Foundation is seeking a Programme Officer to support its work on maternal and perinatal health. The post will...
Cost of goods sold analysis and recommendations to reduce costs of co-packaged mifepristone–misoprostol for medical abortion
One of the key barriers limiting procurement and access to essential reproductive health medicines is affordability in...
Corticosteroids safe and effective for preventing preterm newborn death and respiratory complications in low and middle-income countries
The WHO ACTION-I Trial was a multi-country efficacy trial of antenatal dexamethasone for women at risk of imminent preterm...
Mifepristone for emergency contraception: Case for recommendation in practice guidelines
One in four pregnancies is unintended, threatening the lives and well-being of women and adolescents globally. The risks of...
Self-care and remote care during pregnancy: a new paradigm?
Self-care interventions and remote care offer innovative and equitable ways to strengthen access to sexual and reproductive...
Concept Foundation remembers Dr. Gordon Perkin
Dr. Gordon Perkin, a Canadian physician who was a global health visionary ahead of his time, passed away on 21 August 2020....
Optimal intrapartum care in the twenty-first century
Introducing a new series on intrapartum care in the journal Best Practice and Research in Obstetrics and Gynaecology, Concept...
We Need More Pharmaceutical R&D to Improve Maternal Health
Since the beginning of the Millennium Development Goals period and stretching out to the current Sustainable Development...
Oxytocin quality: evidence to support updated global recommendations on oxytocin for postpartum haemorrhage
Lambert P., McIntosh M.P., Widmer M. et al. Evidence to support updated recommendations on oxytocin for postpartum...
WHO Prequalifies a 2nd generic DMPA product with Concept Foundation support
Concept Foundation is happy to announce that Incepta Pharmaceuticals (Bangladesh) has been awarded WHO Prequalification of their intramuscular (IM) depot medroxyprogesterone acetate (DMPA) 150 mg/ml product.
